Esperion (NASDAQ: ESPR) and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with cardiovascular, and hepatic and renal disease, announce they have entered into a definitive agreement for Esperion to acquire Corstasis. Under the terms of the agreement, Esperion, through a subsidiary, will acquire all outstanding stock of Corstasis in exchange for an upfront payment of $75 million in cash. Corstasis shareholders also will be eligible to receive a total of up to an additional $180 million upon the attainment of certain regulatory and commercial milestones, as well as low double-digit royalties on sales of Enbumyst and follow-on products.
Read the full article: Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis //
Source: https://www.businesswire.com/news/home/20260303929470/en/Esperion-Therapeutics-and-Corstasis-Therapeutics-Announce-Esperions-Definitive-Agreement-to-Acquire-Corstasis-Expanding-Its-Cardiovascular-Franchise-with-Enbumyst-bumetanide-nasal-spray